Similar benefits were observed in newly diagnosed IDH1-mutant AML patients ineligible for standard chemotherapy [111], and in clinical trials of enasidenib treatment in IDH2-mutant AML [112, 113]. The gene discussed is IDH2; the disease is acute myeloid leukemia.